• If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations.
• The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk.
• Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline and portfolio fit within broader sector trends. This context is important because sentiment around the business can influence how much investors are willing to pay for each dollar of expected future performance.
• On Simply Wall St’s valuation checks Alkermes scores a 3 out of 6. Next up is a closer look at how different valuation methods line up on the stock and why there may be an even better way to think about its value by the end of this article.

Approach 1: Alkermes Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return.

For Alkermes, the model uses a 2 Stage Free Cash Flow to Equity approach, starting from last twelve months free cash flow of about $483.3 million. Analyst and extrapolated projections suggest free cash flow in the range of $352.0 million in 2026, rising to a projected $797.5 million by 2030, with further estimates out to 2035. All of these cash flows are in $ and are discounted back to today to account for risk and the time value of money.

Combining these discounted projections gives an estimated intrinsic value of about $93.31 per share. Compared with the current share price of around $35.40, the DCF output suggests Alkermes is trading at a 62.1% discount to this estimate, indicating a wide gap between the current market price and the value suggested by this particular valuation model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alkermes is undervalued by 62.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Alkermes Price vs Earnings

For a profitable company, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. It quickly shows whether the market is putting a richer or more conservative price tag on those earnings compared with other options.

Growth expectations and risk both play a big role in what counts as a “normal” or “fair” P/E. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually points to a lower one.

Alkermes currently trades on a P/E of about 38.6x. That sits above the Biotechs industry average of roughly 17.7x and also above the peer group average of around 20.4x. Simply Wall St’s Fair Ratio for Alkermes is 25.8x, which is its estimate of an appropriate P/E given factors such as Alkermes’ earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry because it adjusts for those company specific features. Set against the current P/E of 38.6x, the Fair Ratio of 25.8x suggests the stock is trading above that tailored estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Alkermes Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, a simple framework that lets you connect your view of Alkermes' story with a set of forecasts for revenue, earnings and margins, and then turn that into a Fair Value that you can compare with the current share price. On Simply Wall St's Community page, Narratives are available as an easy tool used by millions of investors, updating automatically when new information such as news, trial data or earnings is added, so your Fair Value view keeps moving with the story rather than staying frozen in time. For Alkermes, one investor might adopt an optimistic Narrative that leans toward a Fair Value around US$57.33 based on stronger sleep and narcolepsy assumptions. Another might take a more cautious Narrative closer to US$31.30 that reflects concerns about product concentration, pricing pressure and execution risk. By setting a Narrative that matches your own expectations, you can see whether your Fair Value sits nearer the higher end or lower end of the roughly US$30 to US$58 analyst range and use that gap between Fair Value and price to help decide whether Alkermes currently looks attractive, fairly priced or expensive for you.

For Alkermes, here are previews of two leading Alkermes Narratives:

Fair Value: US$57.33

Implied discount to this Fair Value from the recent US$35.40 share price: about 38.3%.

Revenue growth assumption: 18.99% a year.

• Assumes the sleep and narcolepsy franchise, particularly alixorexton, opens up new indications and supports higher earnings than current consensus.
• Builds in improving profit margins over time, helped by psychiatry products, a debt free balance sheet and flexibility for actions such as acquisitions or buybacks.
• Flags real risks around patent expiries, concentration in a few key products, regulatory scrutiny, pricing pressure and rising R&D spend that could challenge this upbeat view.

Fair Value: US$31.30

Implied premium to this Fair Value from the recent US$35.40 share price: about 13.1%.

Revenue growth assumption: 8.97% a year.

• Emphasises reliance on a narrow set of proprietary drugs and ongoing pricing pressure, which could limit how much of the pipeline translates into lasting earnings.
• Assumes higher future P/E multiples are needed to justify the target despite margin pressure, reflecting concern that a lot of the sleep and psychiatry story is already in the price.
• Highlights execution, regulatory and reimbursement risks around the orexin program and broader portfolio that could constrain returns on the current level of R&D investment.

If you want to go beyond these previews and see how community forecasts, risks and valuation work together for Alkermes, it is worth checking the full set of Narratives and using them as a reference point for your own assumptions.To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alkermes on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Alkermes? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.